Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 40 - Any |
Updated: | 4/2/2016 |
Start Date: | July 2009 |
End Date: | July 2028 |
Contact: | Rachel Lei, BS |
Email: | rachel.lei@usoncology.com |
Phone: | 303-418-7607 |
A Phase III Randomized Study Comparing Intensity Modulated Planning Versus 3-Dimensional Planning for Accelerated Partial Breast Radiotherapy
In the setting of radiotherapy as part of breast-conservation therapy for patients with
early stage breast cancer, the novel planning and delivery method of intensity modulated
radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal
external beam radiotherapy, spares more normal breast and lung tissue, and may lead to
improved clinical outcomes.
early stage breast cancer, the novel planning and delivery method of intensity modulated
radiotherapy is an effective and safe alternative to the commonly-used standard 3D-conformal
external beam radiotherapy, spares more normal breast and lung tissue, and may lead to
improved clinical outcomes.
Inclusion Criteria:
- Histologically confirmed disease (AJC Classification): Tis, T1, T2 (≤ 3.0 cm), N0,
M0.
- Microscopic multifocal disease is only allowed when the entire span of identified
disease measures 3.0 cm or less.
- Negative surgical margins ( ≥ 0.2 cm) after final surgery.
- Subjects with infiltrating lobular histologies or high nuclear grade DCIS will be
required to have breast MRI scanning as part of the initial staging to verify
localized disease.
- Subjects with DCIS will be included in the study only if they had an MRI prior to
lumpectomy.
- Findings on MRI scanning revealing relevant suspicion of disease outside of planned
lumpectomy volume should be further evaluated by ultrasound and, if necessary biopsy,
to exclude multicentric/multifocal disease.
- Subjects with malignant calcifications on mammography will be required to have repeat
mammography after surgery to ensure removal of all malignant calcifications.
- Willing to complete additional screening requirements and meet eligibility criteria
as defined in protocol Sec. 4.4.
- Successful placement of fiducial markers for IGRT requiring nonmigrating fiducials.
- PTV to ipsilateral breast ratio (IBR) ≤ 25 %.
- Radiotherapy anticipated to begin within 10 weeks of lumpectomy or re-excision of
margins.
Exclusion Criteria:
- Pregnancy or breast-feeding.
- Have collagen-vascular disease.
- Inadequate surgical margins ( < 0.2 cm) after final surgery.
- Subjects with persistent malignant/suspicious micro-calcifications.
- Gross multifocal disease and microscopic disease greater than 3.0 cm.
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials